Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.
about
Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionAndrogen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence.Considerations on mTOR regulation at serine 2448: implications for muscle metabolism studies.Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer.p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer.Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients.Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis.Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer.High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.Expression of factors and key components associated with the PI3K signaling pathway in colon cancer.
P2860
Q33761801-745368F2-CA51-48A4-B076-0572588CB008Q35706611-361F0E63-F20B-490F-970D-D8737D8616C8Q37727814-DE2005DA-73CB-4DA0-9579-1B2004AE471AQ38931043-143368DA-FCDE-4C89-9E57-2E0D36A73F61Q39144817-C1C7E1DF-11E3-4780-A70A-B0E3B4365D02Q39417832-5E54B45C-4E5E-42C4-B02C-B54ABC97A44EQ39574305-A6743656-BDF2-4E96-B63D-EA8548611BA6Q41134388-9138851A-F2DB-4877-97AA-B58814A32875Q41561734-C6F6E0EB-6836-4BBF-AC04-93F4D2ABC0B7Q41860640-1F5FF0A6-3B86-4DD8-A00A-0777E695EBDAQ41913207-56502597-89D2-4C31-A0E3-409F53C199D3Q42126151-CF0E7913-78F4-4D7F-8ECC-184950656245Q42182491-BA118973-C184-472B-B51B-601CA0F3822FQ43848815-E52C3E99-5BA3-45A9-9E88-F61A78835992Q48030483-DB72FB12-3BA4-46B9-AB5B-7FC02DC1B782Q52649700-FED83596-F6E8-4C9C-88BF-C91391B458B4
P2860
Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Loss of pSer2448-mTOR expressi ...... n ERG-fusion-positive cancers.
@en
Loss of pSer2448-mTOR expressi ...... n ERG-fusion-positive cancers.
@nl
type
label
Loss of pSer2448-mTOR expressi ...... n ERG-fusion-positive cancers.
@en
Loss of pSer2448-mTOR expressi ...... n ERG-fusion-positive cancers.
@nl
prefLabel
Loss of pSer2448-mTOR expressi ...... n ERG-fusion-positive cancers.
@en
Loss of pSer2448-mTOR expressi ...... n ERG-fusion-positive cancers.
@nl
P2093
P2860
P356
P1476
Loss of pSer2448-mTOR expressi ...... n ERG-fusion-positive cancers.
@en
P2093
Arne Ehlers
Guido Sauter
Hüseyin Sirma
Julia Müller
Lia Burkhardt
Markus Graefen
Sarah Minner
Thomas Steuber
Thorsten Schlomm
P2860
P304
P356
10.1002/IJC.27768
P50
P577
2012-08-30T00:00:00Z